Hindustan Bio Sciences Ltd
Hindustan Bio Sciences Ltd (HINDBIO) last reported results for the quarter ended Jun 2026, with sales of ₹0 crore and net profit of ₹-0.11 crore. The stock last traded at ₹7.3, a market capitalisation of ₹7.49 crore. Over the past 52 weeks the stock has ranged between ₹5 and ₹9.92. Figures are as of 6 Oct 2026 and are not real time.
Hindustan Bio Sciences Ltd share price and key metrics
- Current price
- ₹7.3
- Market cap
- ₹7.49 cr
- Book value
- ₹0.81
- ROE
- -3.47%
- ROCE
- -0.91%
- Dividend yield
- 0.00%
- 52w high / low
- 9.92/5.00
Metrics as of 6 Oct 2026. Not real time.
Track Hindustan Bio Sciences Ltd
Cruxal reads every Hindustan Bio Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Hindustan Bio Sciences Ltd growth and returns
- 10 Years
- -5%
- 5 Years
- -6%
- 3 Years
- -7%
- TTM
- -66%
- 10 Years
- 6%
- 5 Years
- 15%
- 3 Years
- 8%
- TTM
- -231%
- 10 Years
- 17%
- 5 Years
- 13%
- 3 Years
- 7%
- 1 Year
- -13%
- 10 Years
- -22%
- 5 Years
- -10%
- 3 Years
- 5%
- Last Year
- -3%
Hindustan Bio Sciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0 cr, down 100.0% from ₹0.32 cr a year earlier. Net profit swung to a loss of ₹0.11 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.41 | 0 | 0.38 | 0.32 | 0 | 0.38 | 0 | 0 |
| Expenses | 0.34 | 0.04 | 0.28 | 0.32 | 0.06 | 0.31 | 0.11 | 0.11 |
| Operating profit | 0.07 | -0.04 | 0.1 | 0 | -0.06 | 0.07 | -0.11 | -0.11 |
| OPM % | 17.07% | — | 26.32% | 0.00% | — | 18.42% | — | — |
| Other income | 0.01 | 0 | 0.01 | 0.01 | 0.01 | 0.02 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 | 0 |
| Profit before tax | 0.08 | -0.04 | 0.11 | 0.01 | -0.05 | 0.08 | -0.11 | -0.11 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | 0.08 | -0.04 | 0.11 | 0.01 | -0.06 | 0.08 | -0.12 | -0.11 |
| EPS (₹) | 0.08 | -0.04 | 0.11 | 0.01 | -0.06 | 0.08 | -0.12 | -0.11 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Hindustan Bio Sciences Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.01 | 1.03 | 3.56 | 1.94 | 1.03 | 0.43 | 0.92 | 1.05 | 0.81 | 0.74 | 0.38 |
| Operating profit | -0.47 | -2.35 | 0.13 | 0.14 | -0.94 | -0.51 | -0.03 | 0.06 | 0.1 | -0.01 | -0.21 |
| OPM % | -46.53% | -228.16% | 3.65% | 7.22% | -91.26% | -118.60% | -3.26% | 5.71% | 12.35% | -1.35% | -55.26% |
| Net profit | -0.49 | -2.28 | 0.11 | 0.08 | -0.94 | -0.52 | -0.04 | 0.06 | 0.1 | -0.08 | -0.21 |
| EPS (₹) | -0.48 | -2.22 | 0.11 | 0.08 | -0.92 | -0.51 | -0.04 | 0.06 | 0.10 | -0.08 | -0.21 |
TTM is the trailing twelve months to the most recent quarter.
Hindustan Bio Sciences Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 2.05 | 2.05 | 2.05 | 2.05 |
| Reserves | -5.92 | -8.20 | -8.09 | -8.01 | -8.95 | -9.46 | -1.30 | -1.25 | -1.15 | -1.22 |
| Borrowings | 1.30 | 1.57 | 3.37 | 2.60 | 1.86 | 2.17 | 2.46 | 2.56 | 2.51 | 2.35 |
| Other liabilities | 0.24 | 0.09 | 0.10 | 0.71 | 0.32 | 0.02 | 0.08 | 0.01 | 0.01 | 0.02 |
| Total liabilities | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.37 | 3.42 | 3.20 |
| Fixed assets | 0.06 | 0.06 | 0.06 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other assets | 5.81 | 3.65 | 5.57 | 5.50 | 3.44 | 2.94 | 3.26 | 3.34 | 3.39 | 3.19 |
| Total assets | 5.87 | 3.71 | 5.63 | 5.55 | 3.48 | 2.98 | 3.29 | 3.37 | 3.42 | 3.20 |
As reported by the company. Total assets equal total liabilities by construction.
Hindustan Bio Sciences Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -0.16 | -0.23 | -1.32 | 0.82 | 0.75 | -0.34 | -0.05 | -1.41 | 0.03 | 0.28 |
| Cash from investing | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Cash from financing | 0.18 | 0.21 | 1.50 | -0.81 | -0.93 | 0.34 | 0.05 | 1.43 | -0.05 | -0.16 |
| Net cash flow | 0.01 | -0.02 | 0.17 | 0.01 | -0.18 | -0.01 | 0.00 | 0.03 | -0.02 | 0.12 |
| Free cash flow | -0.16 | -0.23 | -1.33 | 0.82 | 0.75 | -0.34 | -0.05 | -1.41 | 0.03 | 0.27 |
| CFO / operating profit | 34% | 10% | -1,015% | 600% | -78% | 67% | 167% | -2,350% | 30% | -2,800% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Hindustan Bio Sciences Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -8.43% | -49.08% | 2.62% | 2.51% | -23.75% | -16.67% | -1.30% | 1.52% | 2.95% | -0.91% |
| Debtor days | 169.85 | 113.40 | 171.22 | 255.88 | 219.71 | 118.84 | 178.53 | 152.95 | 198.27 | 24.66 |
| Inventory days | 0.00 | 51.23 | 13.89 | 95.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days payable | — | 44.82 | 7.58 | 185.31 | — | — | — | — | — | — |
| Cash conversion cycle | 169.85 | 119.80 | 177.54 | 166.03 | 219.71 | 118.84 | 178.53 | 152.95 | 198.27 | 24.66 |
| Working capital days | -191.53 | -170.10 | 85.10 | 86.55 | -148.83 | -500.81 | -226.14 | 312.86 | 441.60 | 305.81 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Hindustan Bio Sciences Ltd shareholding pattern
Promoters held 12.19% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 12.19% | 12.19% | 12.19% | 12.19% | 12.19% | 12.19% | 12.19% | 12.19% |
| Public | 87.81% | 87.82% | 87.80% | 87.81% | 87.81% | 87.81% | 87.80% | 87.81% |
| No. of shareholders | 11,618 | 11,276 | 11,246 | 11,620 | 11,405 | 11,516 | 11,530 | 11,707 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Hindustan Bio Sciences Ltd corporate filings
- Hindustan Bio Sciences Ltd. Conducts AGM with Full Approval of Resolutions; No Major Financial Changes ReportedAGM/EGMlow impact
Cruxal's analysis: Hindustan Bio Sciences Ltd. held its 34th AGM on 30th September 2026, with all agenda…
Read the full analysis - Hindustan Bio Sciences Limited holds AGM with no significant financial disclosures or strategic updatesAGM/EGMlow impact
Cruxal's analysis: Hindustan Bio Sciences Limited conducted its 34th AGM on September 30, 2026, with 39…
Read the full analysis - The Trading window for dealing in the securities of the company will remain closed from 1st October 2026 till 48 hours after the announcement of standalone Un-audited Financial results ....Insider Trading / SASTlow impact
- Hindustan Bio Sciences Ltd announces 34th Annual General Meeting, Book Closure, and E-votingCompany Updatelow impact
Cruxal's analysis: Hindustan Bio Sciences Ltd has released the newspaper publication regarding its 34th…
Read the full analysis - Hindustan Bio Sciences Limited Proposes Capital Reduction to Write Off Accumulated LossesAGM/EGMhigh impact
Cruxal's analysis: Hindustan Bio Sciences Limited has announced a scheme to reduce its paid-up share capital…
Read the full analysis - Hindustan Bio Sciences Ltd submits 34th Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Hindustan Bio Sciences Ltd has filed its 34th Annual Report, including the notice for the…
Read the full analysis - Hindustan Bio Sciences Limited Announces Capital Reduction and Share Consolidation to Clean Up Balance SheetBoard Meetingmedium impact
Cruxal's analysis: Hindustan Bio Sciences Limited has proposed a scheme of capital reduction and…
Read the full analysis - Hindustan Bio Sciences Limited Announces Board Meeting to Consider Scheme of Reorganization of Share CapitalBoard Meetingmedium impact
Cruxal's analysis: Hindustan Bio Sciences Limited has scheduled a board meeting for August 31, 2026, to…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.